**Table S2. Treatment outcomes in 17 patients with EER**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient No./Age (year)/Sex** | **Type of EER/Time to EER (months)** | **Treatment for EER** | **BOR upon treatmenta** | **Time to progression (months)** | **Follow-up period (months)b** | **Final status** |
| 1/53/M | MN/5.9 | REOP | PD | 5.2 | 14.4 | Death |
| 2/47/M | MN/5.8  | TACE | PD | 2.1 | 4.7 | Death |
| 3/41/M | MN/5.8  | TACE and Len | PD | 3.9 | 9.3 | Death |
| 4/45/M | DI/1.1  | TACE | PD | 1.8 | 2.7 | Death |
| 5/87/M | MN/3.2  | TACE and Sor | PR | 10.1 | 16.9 | Death |
| 6/49/M | MN/3.3 | TACE and Len | PR | not reached | 32.7 | Alive |
| 7/77/M | DI/2.9  | TACE | PD | 1.8 | 2.7 | Death |
| 8/45/M | DI/2.6  | TACE, Sor and PD-1 mAb | SD | 9.1 | 14.3 | Death |
| 9/31/M | MN/3.1  | REOP | PD | 3.1 | 16.4 | Death |
| 10/67/M | DI/3.1  | TACE, Sor and PD-1 mAb (Cam) | PR | 7.2 | 19.5 | Alive |
| 11/31/F | MN/3.1  | TACE | PR | 6.1 | 9.2 | Death |
| 12/42/M | MN/1.4  | TACE | PD | 2.1 | 3.6 | Death |
| 13/54/M | MN/4.3  | TACE, Len and PD-1 mAb | PR | not reached | 12.9 | Alive |
| 14/58/M | DI/2.2  | TACE, Len and PD-1 mAb | PD | 2.7 | 7.1 | Death |
| 15/59/M | MN/3.7  | TACE, Len and PD-1 mAb | SD | not reached | 5.0 | Alive |
| 16/67/M | MN/1.8  | TACE, Len and PD-1 mAb | PD | 5.9 | 6.0 | Alive |
| 17/59/M | DI/3.4  | TACE and Len | PR | not reached | 3.9 | Alive |

Notes:

a Response evaluation was based on the mRECIST 1.1 criteria.

b Time period followed since the occurrence of EER.

Abbreviations: BOR, best overall response; Cam, camrelizumab; DI, diffusely infiltrative subtype; EER, early explosive recurrence; F, female; Len, lenvatinib; M, male; MN, multiple nodular subtype; PD, progressive disease; PR, partial remission; SD, stable disease; Sor, sorafenib; TACE, trans-arterial chemoembolization.